Revenue segments as reported by the company.

Diabetes

Oncology

Immunology

Neuroscience

Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Marketing, selling and administrative

Acquired in-process research and development

Asset impairment, restructuring and other special charges

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Eli Lilly

Cialis, ia a competitor to Pfizer's blockbuster Viagra for erectile dysfunction. Cialis maintains an active period of 36 hours.

Cialis

Cymbalta is a serotonin-norepinephrine reuptake inhibitor used predominantly in the treatment of major depressive disorders and generalized anxiety disorder, ranks with Prozac as one of the most financially successful pharmaceuticals in industry history. It is also used in the treatment of fibromyalgia, neuropathy, chronic pain and osteoarthritis.

Cymbalta

Gemzar is a treatment of pancreatic cancer. Gemzar is commonly used in the treatment of pancreatic cancer, usually in coordination with 5-FU chemotherapy and radiology. Gemzar also is routinely used in the treatment of non-small cell lung cancer.

Gemzar

Methadone is an analgesic used frequently in the treatment of heroin, opium and other opioid and narcotic drug addictions.

Methadone

Prozac was one of the first therapies in its class to treat clinical depression by blocking the uptake of serotonin within the human brain. It is prescribed to more than fifty-four million people worldwide.

Prozac

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Eli Lilly reports robust Q4 earnings, eyes growth in innovative therapies

Eli Lilly's Q4 2022 earnings call highlighted strong financial performance, pipeline advancements, and strategic initiatives for future growth.
The company's focus on innovation, FDA approvals, and market expansion underscores its commitment to addressing unmet medical needs and driving shareholder value.
Challenges in physician education, obesity treatment development, and market access present areas for strategic focus and investment for sustained growth.
Opportunities in expanding manufacturing capacity, engaging with payers, and capitalizing on consumer interest in obesity treatments position Lilly for continued success in 2023.

Eli Lilly reports robust Q1 growth amidst capacity challenges

Eli Lilly's Q1 2023 performance reflects strong revenue growth and strategic investments in new products and facilities.
While facing challenges in capacity and supply pressure, the company's focus on pipeline advancements and market opportunities positions it for future growth.
Opportunities in international markets, cardiovascular trials, and product promotion present avenues for continued expansion and revenue growth.
Overall, Eli Lilly's financial performance, product strengths, and strategic initiatives demonstrate a resilient and growth-focused approach.

Eli Lilly reports robust Q2 earnings, eyes growth through innovation

Eli Lilly's Q2 earnings call showcased strong financial performance, revenue growth, and advancements in its pipeline, driven by key products and strategic investments.
The company faces challenges in managing increased expenses, supply chain constraints, and regulatory considerations, requiring strategic decision-making and operational agility.
Opportunities lie in expanding market access, leveraging innovative treatments like tirzepatide, and enhancing manufacturing capabilities to drive future growth and competitive advantage.
Overall, Lilly's focus on innovation, market expansion, and addressing health needs positions it well for sustained growth and leadership in the pharmaceutical industry.

Eli Lilly posts robust Q3 results, eyes expansion and commercial growth

Eli Lilly (LLY) showcased strong financial performance and pipeline advancements in Q3 2023.
Challenges include supply restrictions and pricing decisions, but opportunities lie in expansion plans and commercial coverage ramp-up.
Investors advised to focus on guidance range for insights into 2024 expectations.

Eli Lilly posts robust Q4 results, eyes global expansion opportunities

Eli Lilly's strong financial performance in Q4 2023, driven by revenue growth and operational efficiency, sets a solid foundation for future growth.
The company's strategic acquisitions, global expansion plans, and focus on innovation position it well for continued success and market leadership.
Challenges in drug development and manufacturing require careful navigation, but opportunities in new drug trials and market expansion offer avenues for growth.
Overall, Eli Lilly's 2023 was marked by productivity and anticipation of sustained momentum in 2024, reflecting a positive outlook for the company.

Eli Lilly reports robust Q1 growth, eyes pipeline opportunities

Eli Lilly's Q1 performance showcased strong revenue growth, driven by new products and global market expansion.
While facing challenges like low Zepbound volume and manufacturing complexities, Lilly's strengths in innovation and market presence position it well for growth.
Opportunities in pipeline advancements, differentiation in drug portfolios, and potential Alzheimer's treatments signal a promising future for the company.
Overall, Eli Lilly's strategic focus on growth, innovation, and market expansion sets a positive trajectory for continued success.

Eli Lilly reports stellar Q3 results, eyes global expansion opportunities

Eli Lilly's Q3 performance reflects robust revenue growth, driven by new products and strategic investments, positioning the company for continued success.
Key pipeline advancements and revenue guidance raise optimism for future growth, with a focus on global scaling and market expansion initiatives.
Challenges in patient adherence and treatment efficacy are being addressed, while opportunities in market penetration and revenue growth are actively pursued.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novo Nordisk

A clinical-stage biotech is coming for their lunch. It aims to advance its own weight-loss drug to a phase 3 clinical study in the very near future.

Why Weight Loss Drug Developer Stocks Tumbled on Thursday

AstraZeneca

FTAI Aviation Ltd

MercadoLibre

SPS Commerce

Wall Street has rewarded certain growth stocks handsomely this year. I believe now may be an opportune time to buy some of these high-flyers, even after the recent tech selloff.

7 Explosive Growth Stocks Set to Soar in 2024

Arista Networks

Super Micro Computer

After Wednesday's painful market-wide sell-off, investors seem more willing than ever to give up on the big-tech trade. Indeed, the Magnificent Seven was crushed as two members reported quarterly results that failed to impress.

3 Top-Performing Stocks Beating the Big Names in 2024

Sometimes, the success of a company can take the stock so high that it pushes investors away. It is due to this reason that the management announces a stock split.

3 Companies Gearing Up for a Stock Split

INDIANAPOLIS , July 25, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will announce its second-quarter 2024 financial results on Aug. 8, 2024. Lilly will also conduct a conference call that day with the investment community and media to further detail the company's financial performance.

Lilly Confirms Date and Conference Call for Second-Quarter 2024 Financial Results Announcement

Eli Lilly's stock has surged 88.5% in the past year, driven by weight loss drugs. Approval of tirzepatide for weight management in China and the EU opens up new markets for the company. Despite strong growth potential, Eli Lilly's stock remains pricey, with upcoming earnings report potentially changing the investment outlook.

Eli Lilly and Company: The Floodgates To Growth Keep Opening, A Big Win In China

Experimental drug will move to late-stage trials, accelerating development timeline

Viking's stock pops as obesity-drug contender drags down Eli Lilly, Novo Nordisk

Broadcom

Mastercard

Eli Lilly has some exciting opportunities in weight loss in the future, but investors shouldn't overlook its impressive dividend. Broadcom's business is booming due to artificial intelligence, and that can lead to more rate hikes to its dividend.

3 Dividend Growth Stocks That Have Doubled Their Payouts in 5 Years

Eli Lilly has gained attention in recent time thanks to its weight-loss drugs. Demand for these products is driving revenue higher.

If You'd Invested $10,000 in Eli Lilly Stock 5 Years Ago, Here's How Much You'd Have Today

In the most recent trading session, Eli Lilly (LLY) closed at $865.97, indicating a +0.99% shift from the previous trading day.

Eli Lilly (LLY) Advances But Underperforms Market: Key Facts

Apple

Costco

We're still early in the second-quarter earnings cycle. So far, it has mostly been the banks and credit card companies that have reported Q2 results.

Don't Delay! 3 Stocks to Buy BEFORE Q2 Earnings.

Morphic Holding Inc

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Morphic Holding, Inc. (NasdaqGM: MORF) to Eli Lilly and Company (NYSE: LLY). Under the terms of the proposed transaction, shareholders of Morphic will receive $57.00 in cash for each share of Morphic that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequa.

MORPHIC HOLDING INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Morphic Holding, Inc. - MORF

Eli Lilly and Co. (LLY) announced on its WeChat account Friday that it has won approval from Chinese regulators to sell tirzepatide for weight loss in the country.

Eli Lilly Gets Green Light to Sell Weight-Loss Drug in China

Eli Lily's Mounjaro, a weight management drug, has successfully received regulatory approval in China, sending its stock price up during trading today.

Eli Lilly secures weight loss drug approval in China: How do rivals stack up?

Eli Lilly said in a social media post Friday its weight loss drug tirzepatide had received approval from Chinese regulators, further intensifying competition with its Danish rival Novo Nordisk in the key Asian market.

Eli Lilly's weight loss drug tirzepatide gets approval in China

Eli Lilly & Co.'s stock was on pace for its worst day in about three years Thursday as investors fretted about intensifying competition among obesity-drug developers.

Eli Lilly's stock plunges as investors eye obesity-drug competition

Wingstop

The stock market continues to demonstrate strong performance, with the Dow Jones recently achieving a new record high above 40,000 points. Several factors contributed to this upward movement, including better-than-expected quarterly earnings from major banks.

3 High-Flying Stocks That Show No Signs of Slowing Down

Alphabet

Microsoft

Blue-chip stocks are considered to be the most reliable stocks in the industry. Whether you are a beginner or a professional investor, there is nothing like putting your money in blue-chip stocks and holding them long-term.

3 Reliable Blue-Chip Stocks to Buy, Hold and Never Let Go

Eli Lilly's surging valuation has made the case for a stock split. Many growth stocks have deployed stock splits in recent years, including Eli Lilly rival Novo Nordisk.

Will Eli Lilly Do a Stock Split in 2024?

Merck

Pfizer

Eli Lilly, Novo Nordisk, Merck and Pfizer have been highlighted in this Industry Outlook article.

Zacks Industry Outlook Eli Lilly, Novo Nordisk, Merck and Pfizer

Roche Holding AG

The potential of a once-a-day pill for obesity unsettled the weight loss stocks. Shares in Novo Nordisk (NYSE:NVO) and Eli Lilly and Co (NYSE:LLY) were off 4% and 2% respectively on news that Roche's new pill had shown promise in early-stage clinical trials.

Does Roche have weight-loss giants Novo Nordisk and Eli Lilly on the run?

Shares of weight-loss drug developers including Eli Lilly & Co., Novo Nordisk and Structure Therapeutics fell sharply early Wednesday after Roche Holding AG announced early-stage trial data for its experimental obesity pill.

Roche obesity-pill trial results weigh on shares of Eli Lilly, Novo Nordisk

Eli Lilly and Novo Nordisk fell Wednesday after Roche released positive early-stage trial data on its oral weight-loss drug.

Eli Lilly, Novo Nordisk Fall As Roche Releases Weight-Loss Drug Data

Netflix

Eli Lilly's phenomenal growth prospects could take its valuation past $1 trillion. Netflix's strong margins make it the best streaming stock to invest in today.

3 Unstoppable Stocks That You Can Buy and Hold for Years

Novo Nordisk and Eli Lilly shares slid Wednesday on promising early-stage trial data from Roche's latest obesity drug candidate. Roche said its experimental once-daily pill showed average weight loss of 6.1% in four weeks.

News for Eli Lilly Stock (LLY)